Aratana Therapeutics (PETX) Receives Media Sentiment Rating of 0.09

News stories about Aratana Therapeutics (NASDAQ:PETX) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aratana Therapeutics earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.4996566708489 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

Aratana Therapeutics (PETX) traded up $0.15 on Monday, reaching $5.73. 503,200 shares of the company’s stock traded hands, compared to its average volume of 413,858. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26. Aratana Therapeutics has a 1-year low of $4.97 and a 1-year high of $8.63.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.03. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The firm had revenue of $6.16 million for the quarter, compared to analysts’ expectations of $6.47 million. During the same quarter in the prior year, the business earned ($0.38) EPS. The business’s quarterly revenue was up 1440.0% on a year-over-year basis. analysts expect that Aratana Therapeutics will post -1.03 EPS for the current year.

Several analysts recently commented on PETX shares. Lake Street Capital cut their price objective on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 25th. ValuEngine downgraded shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Jefferies Group reissued a “buy” rating and set a $8.00 price objective on shares of Aratana Therapeutics in a research report on Friday, November 3rd. Zacks Investment Research upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research note on Thursday, November 9th. Finally, HC Wainwright began coverage on shares of Aratana Therapeutics in a research note on Friday, November 17th. They set a “buy” rating and a $10.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Aratana Therapeutics has an average rating of “Hold” and a consensus price target of $8.75.

In related news, COO Brent Standridge sold 10,000 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $6.11, for a total value of $61,100.00. Following the completion of the transaction, the chief operating officer now directly owns 70,267 shares of the company’s stock, valued at $429,331.37. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $5.70, for a total transaction of $5,075,941.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,117,032 shares of company stock valued at $6,559,891. Insiders own 5.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply